Is Roivant Sciences Ltd. (ROIV) a Buy, Sell, or Hold?
NASDAQ : ROIV
Roivant Sciences Ltd.
$33.32 USD
-$0.59 (-1.74%)
- Volume
- 5.93M
- Average Volume
- 5.81M
- Market Capitalization
- $24.07B
- P/E Ratio
- -74.04
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $37.00
- Year Low
- $10.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.37
Company Overview
NASDAQ
Matthew Gline
Biotechnology
Healthcare
ROIV
721
GB
USD
Liquidity Metrics
0.02
18.37
18.37
5.06
0.00
Sales & Valuation
$8.26M
2914.11
5.17
-31.73
-1.08
Profitability
-$0.43
-$299.77M
-3629.19%
-3203.12%
-6.85%
-5.23%
P/E Metrics
-74.04
0.88
0.88
Analyst Price Target & Rating
$38.00
$42.00
$30.00
2/5
15 Analysts
-12.32%
Financial Health Scores
34.49
1/9
$4.89B
$5.73B
$435.63M
-$264.58M
Key Metrics (TTM)
$23.18B
2806.43
-88.74
18.37
-6.85%
-23.55%
-1.26%
-3.10%
29789 days
Company Executives
| Name | Title |
|---|---|
| Mayukh Sukhatme | President, Chief Investment Officer & Director |
| Deya Corzo | Chief Medical Officer-In-Residence |
| Matthew Gline | Chief Executive Officer & Director |
| Eric Venker | President & Chief Executive Officer of Immunovant |
| Frank Torti | President & Vant Chair |
| Huafeng Xu | Chief Technology Officer |
| Alex Gasner | Executive Vice President of Roivant Health |
| Ian Rosenblum | Chief Information Officer |
| Josh Chen | General Counsel |
| Jennifer Humes | Chief Accounting Officer |
| Kelly Graff | Head of People |
| Richard Pulik | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Roivant Sciences Ltd. (NASDAQ:ROIV) Stock
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom. ...
Bank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIV
2026-07-25 05:15:06
Bank of Nova Scotia cut its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 7.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,310,387 shares of the company's stock after selling 112,613 shares during the quarter. Bank of Nova Scotia
Allspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIV
2026-07-25 04:21:19
Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences Ltd. (NASDAQ: ROIV) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 142,134 shares of the company's stock, valued at approximately $3,957,000. Other hedge funds also recently added to or reduced their stakes
2026-07-23 16:05:00
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update.
2026-07-23 16:05:00
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens.
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
2026-07-07 06:15:00
Roivant Sciences anticipates three commercial launches over the next few years, led by brepocitinib. The stock is arguably expensive now, even with aggressive revenue estimates for 2031.
2026-06-09 20:22:12
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-06-03 18:32:01
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
2026-05-29 17:24:06
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Frequently Asked Questions
-
What is the current Roivant Sciences Ltd. (ROIV) stock price?
-
Roivant Sciences Ltd.(NASDAQ:ROIV) stock price is $33.32 in the last trading session. During the trading session, ROIV stock reached the peak price of $37 while $10.9 was the lowest point it dropped to. The percentage change in ROIV stock occurred in the recent session was --1.74% while the dollar amount for the price change in ROIV stock was -$0.59.
-
ROIV's industry and sector of operation?
-
The NASDAQ listed ROIV is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ROIV?
-
Mayukh Sukhatme | President, Chief Investment Officer & Director
Deya Corzo | Chief Medical Officer-In-Residence
Matthew Gline | Chief Executive Officer & Director
Eric Venker | President & Chief Executive Officer of Immunovant
Frank Torti | President & Vant Chair -
How many employees does ROIV have?
-
Number of ROIV employees currently stands at 721. ROIV operates from 11-12 St. James's Square, London, GL SW1Y 4LB, GB.
-
Link for ROIV official website?
-
Official Website of ROIV is: https://roivant.com
-
How do I contact ROIV?
-
ROIV could be contacted at phone #44 2074 003 347 and can also be accessed through its website. ROIV operates from 11-12 St. James's Square, London, GL SW1Y 4LB, GB.
-
How many shares of ROIV are traded daily?
-
The average number of ROIV shares traded daily for last 3 months was 5.81M.
-
What is the market cap of ROIV currently?
-
The market value of ROIV currently stands at $24.07B with its latest stock price at $33.32